Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Revvity Inc (RVTY) Price & Performance

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Revvity Inc — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.02, while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc pays a 0.25% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Revvity Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.

QDTYRVTY
Sector
Income / Options OverlayTechnology
52-Week High
$46.71$117.75
52-Week Low
$36.57$82.26
Market Cap
$12.33B
Enterprise Value
$14.82B
Dividend Yield
0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY trades at $39.53 with minimal daily movement (+0.15%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The stock faces immediate resistance at $40 and support at $39. Recent corporate actions include consistent weekly dividend distributions, with amounts ranging from $0.22 to $0.32 per share throughout 2026.

The outlook remains cautious given the bearish technical signals and lack of available fundamental data. While the consistent dividend payments provide some income stability, the absence of key financial metrics like P/E ratio and profitability measures limits fundamental analysis. Investors face uncertainty regarding the company's financial health and growth prospects without current earnings data.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.

The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.

Read more on QDTY

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY